Lake Street analyst Brooks O’Neil affirmed a Buy rating on Tandem Diabetes Care (TNDM) and raised his price target to $60 from $35 following the U.S. commercial launch of its t:slim X2 insulin pump with Basal-IQ, which is integrated with Dexcom’s (DXCM) G6 CGM. In a research note to investors, O’Neil contends that while the stock is up 36.4% in the 14 trading days since its Q2 earnings release, he believes it is “just getting going.”
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.